Clinical trials: Solid Tumors, completed
Cancer
Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors
The purpose of this study is to test the safety of PRLX 93936 and see what kind of effect it has on patients and their cancer. This study will also determine the highest dose of PRLX 93936 that can be given without causing…
- Trial name
- NCT00528047
- Testing
- PRLX 93936
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Prolexys Pharmaceuticals
Advanced Non-Hematologic Malignancies
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic…
- Trial name
- NCT01653158
- Testing
- CP-751,871, Docetaxel
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Pfizer
Advanced Solid Neoplasm
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).
- Trial name
- NCT03330106
- Testing
- Pevonedistat, Docetaxel, Carboplatin
- Where
- 8 sites in United States
- Volunteers
- 68 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor
Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer
The objective of the study is to evaluate tolerability and safety of CBT101 in patients who underwent curative surgery and adjuvant therapy for solid cancer
- Trial name
- NCT04557306
- Testing
- CBT101 cells, every 2 weeks, CBT101 cells, every 4 weeks
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- CHABiotech CO., Ltd
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth
This study evaluates the effects of the Survivorship Wellness Group Program following active treatment, as well as to learn from Survivorship Wellness participants about their concerns regarding the current COVID-19 pandemic.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04630015
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- University of California, San Francisco
Metastatic Solid Tumors
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
- Trial name
- NCT04319198
- Testing
- Sacituzumab Govitecan-hiy
- Where
- 21 sites in United States, Belgium and 1 more
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Solid Tumors, Virally Mediated Cancers and Liposarcoma
A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
The purpose of this study is to determine whether 5-azacitidine in combination with romidepsin cancer are effective in the treatment of advanced solid tumors.
- Trial name
- NCT01537744
- Testing
- oral 5-azacitidine in combination with romidepsin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the bad side effects of…
- Trial name
- NCT00003144
- Testing
- amifostine trihydrate, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- NYU Langone Health
Solid Tumors, Lymphoma, Non-Hodgkin
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
The study will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered as an intravenous infusion on Days 1, 8 and 15 of each 28 day cycle in participants with solid…
- Conditions
- Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic. B-Cell
- Trial name
- NCT00871663
- Testing
- SCH 727965
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Hormone Receptor-Positive Breast, Gynecologic
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Background: Some types of cancer cells that have hormone receptors on their surfaces need the hormone estrogen to grow. The drug tamoxifen blocks estrogen from binding to the tumor cells, which helps to slow or stop the growth of…
- Conditions
- Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
- Trial name
- NCT01273168
- Testing
- Z-Endoxifen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
EF5 in Treating Patients With Solid Tumors
Diagnostic procedures using the drug EF5 to detect the presence of oxygen in tumor cells may help to plan effective treatment for solid tumors.
- Trial name
- NCT00003282
- Testing
- EF5, therapeutic conventional surgery, biopsy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors
BRF116056 is the first clinical experience with GSK2118436, a BRAF inhibitor, in Japan. This study will be designed to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 in…
- Trial name
- NCT01582997
- Testing
- GSK2118436
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
This is a world wide phase 1/2, open-label, study of neratinib in combination with capecitabine, conducted in 2 parts. In Part 1, 3 to 9 subjects with solid tumors will be enrolled in each dose group of the combination of…
- Trial name
- NCT00741260
- Testing
- Neratinib, Capecitabine
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 105 people
- Sponsor
- Puma Biotechnology, Inc.
Solid Tumors
Phase I Trial of ZIO-101 in Patients With Solid Tumors
Primary Objectives: 1. To determine the toxicities and maximum tolerated dose (MTD) of ZIO-101 when administered intravenously once a day for 5 consecutive days every 4 weeks in subjects with advanced solid tumors. 2.
- Trial name
- NCT00509782
- Testing
- ZIO-101
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor Malignancy or Hematologic Malignancy
Scripps Tumorgraft Study
Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.
- Trial name
- NCT01726699
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Scripps Translational Science Institute
Solid Tumors, Brain Metastases
18F ML-10 for Early Detection of Response of Brain Metastases to WBRT
The purpose of this study is to evaluate the potential of [18F]-ML-10 to serve as a non-invasive imaging tool for the early detection of apoptosis in brain metastases in response to radiation therapy.
- Trial name
- NCT00791063
- Testing
- 18F ML-10
- Volunteers
- 10 people
- Sponsor
- Aposense Ltd.
Carcinoma, Advanced Cancer
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT02507544
- Testing
- TRX-818 capsules
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- TaiRx, Inc.
Cancer
An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors
The study is a Phase 1, open-label study designed to characterize the absorption, distribution, metabolism and excretion of GSK2118436 following administration of a single oral 14C labeled dose of GSK2118436 as a suspension in…
- Trial name
- NCT01262963
- Testing
- GSK2118436
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Neoplasms
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.
- Trial name
- NCT04397276
- Testing
- JNJ-70218902
- Where
- 7 sites in Canada, Israel and 1 more
- Volunteers
- 82 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.